{"id":"rituximab-375","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"20-30","effect":"Infections"},{"rate":"10-20","effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"1-5","effect":"Tumor lysis syndrome"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets CD20, a surface antigen expressed on B lymphocytes. By binding to CD20, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B cell depletion. This mechanism is effective in B-cell malignancies and autoimmune diseases where B cells play a pathogenic role.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:19.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma (B-cell)"},{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Rheumatoid arthritis"},{"name":"Granulomatosis with polyangiitis (GPA)"},{"name":"Microscopic polyangiitis (MPA)"}]},"trialDetails":[{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT07494565","phase":"PHASE2","title":"Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-05","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive","enrollment":60},{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":"Lymphoma","enrollment":95},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT02682641","phase":"PHASE2","title":"Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2016-05-18","conditions":"Mantle Cell Lymphoma","enrollment":50},{"nctId":"NCT07492407","phase":"","title":"CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04","conditions":"MZL","enrollment":131},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT02446236","phase":"PHASE1","title":"Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2015-06-18","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT01808911","phase":"PHASE3","title":"Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2012-05","conditions":"Acquired Haemophilia","enrollment":110},{"nctId":"NCT04384484","phase":"PHASE3","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2020-09-16","conditions":"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":440},{"nctId":"NCT04998669","phase":"PHASE2","title":"Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2022-02-11","conditions":"Follicular Lymphoma","enrollment":100},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT04931368","phase":"PHASE3","title":"OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klinikum Stuttgart","startDate":"2021-06-28","conditions":"Primary Central Nervous System Lymphoma","enrollment":331},{"nctId":"NCT05100862","phase":"PHASE3","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2022-03-10","conditions":"Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":780},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT05624554","phase":"PHASE3","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-16","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":300},{"nctId":"NCT05011422","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-11-03","conditions":"Pediatric Hematologic Malignancies","enrollment":50},{"nctId":"NCT03523975","phase":"PHASE1, PHASE2","title":"Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-12-24","conditions":"Mantle Cell Lymphoma","enrollment":28},{"nctId":"NCT05947851","phase":"PHASE3","title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma","enrollment":735},{"nctId":"NCT01804712","phase":"EARLY_PHASE1","title":"Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy","status":"COMPLETED","sponsor":"Christopher Kane","startDate":"2013-07","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT00492050","phase":"PHASE2","title":"Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08-02","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT07104032","phase":"PHASE3","title":"IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2026-03","conditions":"Relapsed/Refractory Primary Central Nervous System Lymphoma","enrollment":132},{"nctId":"NCT01419561","phase":"PHASE2","title":"Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-08","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8","enrollment":140},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT03458260","phase":"PHASE2","title":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-12-26","conditions":"Aggressive Non-Hodgkin Lymphoma","enrollment":74},{"nctId":"NCT03336333","phase":"PHASE3","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2017-10-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":590},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT04075292","phase":"PHASE3","title":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-01-20","conditions":"Untreated Chronic Lymphocytic Leukemia","enrollment":155},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT06364423","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia","enrollment":132},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT03919175","phase":"PHASE2","title":"Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-09-01","conditions":"Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1","enrollment":18},{"nctId":"NCT04268277","phase":"PHASE2","title":"Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY","status":"TERMINATED","sponsor":"University of Ulm","startDate":"2022-03-01","conditions":"Marginal Zone Lymphoma","enrollment":22},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT04421560","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Ibrutinib and Rituximab in PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer","enrollment":37},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT05389423","phase":"PHASE1","title":"Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma","enrollment":25},{"nctId":"NCT07418190","phase":"PHASE2","title":"Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-01","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":33},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT05551936","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaishalee Kenkre","startDate":"2023-01-26","conditions":"Follicular Lymphoma","enrollment":42},{"nctId":"NCT07415980","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-04-01","conditions":"Double Expressor DLBCL","enrollment":68},{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT07405255","phase":"PHASE2","title":"Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-01-30","conditions":"Central Nervous System Lymphoma","enrollment":19},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT01516580","phase":"PHASE3","title":"Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-12","conditions":"B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type","enrollment":482},{"nctId":"NCT01516567","phase":"PHASE2","title":"Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2012-04-01","conditions":"Primary Mediastinal Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT07397832","phase":"PHASE2","title":"CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":58},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT06350318","phase":"PHASE2","title":"Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-04-19","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma","enrollment":43},{"nctId":"NCT07389356","phase":"NA","title":"Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-25","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":70},{"nctId":"NCT04884035","phase":"PHASE1","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","status":"RECRUITING","sponsor":"Celgene","startDate":"2021-09-15","conditions":"Lymphoma, B-Cell","enrollment":174},{"nctId":"NCT04624906","phase":"PHASE2","title":"Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-03-02","conditions":"Waldenstrom Macroglobulinemia","enrollment":63},{"nctId":"NCT04161248","phase":"EARLY_PHASE1","title":"Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2020-09-02","conditions":"Lymphoma, B-Cell","enrollment":18},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":"Diffuse Large B Cell Lymphoma, DLBCL, Cancer","enrollment":27},{"nctId":"NCT01446133","phase":"PHASE2","title":"Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-12-12","conditions":"Leukemia, Lymphoma","enrollment":120},{"nctId":"NCT05737628","phase":"PHASE1","title":"First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228","status":"ACTIVE_NOT_RECRUITING","sponsor":"Byondis B.V.","startDate":"2024-03-04","conditions":"Lymphoma","enrollment":17},{"nctId":"NCT06647732","phase":"PHASE2","title":"Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-30","conditions":"Mucosa-associated Lymphoid Tissue Lymphoma (MALT)","enrollment":42},{"nctId":"NCT03697512","phase":"PHASE2","title":"MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-09-27","conditions":"Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma","enrollment":175},{"nctId":"NCT05735834","phase":"PHASE3","title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2024-05-21","conditions":"Splenic Marginal Zone Lymphoma","enrollment":122},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT06835530","phase":"PHASE2","title":"A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2025-04-09","conditions":"Diffuse Large B Cell Non-Hodgkin Lymphoma","enrollment":47},{"nctId":"NCT04604067","phase":"PHASE2","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2021-06-25","conditions":"Diffuse Large B-cell Lymphoma","enrollment":260},{"nctId":"NCT01350882","phase":"PHASE3","title":"Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2008-10","conditions":"Humoral Rejection in Kidney Transplantation","enrollment":40},{"nctId":"NCT03467867","phase":"PHASE2","title":"A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2018-04-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":25},{"nctId":"NCT06756308","phase":"PHASE2","title":"A Study of Enasidenib in People With T-Cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-24","conditions":"T-cell Lymphoma","enrollment":25},{"nctId":"NCT04182204","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":270},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT04594798","phase":"PHASE2","title":"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2021-09-20","conditions":"DLBCL, Lymphoma, B-Cell","enrollment":39},{"nctId":"NCT07189065","phase":"PHASE2","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2025-11-27","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT07272499","phase":"PHASE2","title":"Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-10","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":25},{"nctId":"NCT05494593","phase":"PHASE4","title":"A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2023-02-28","conditions":"Mucopolysaccharidosis (MPS), Hunter Syndrome","enrollment":""},{"nctId":"NCT07270835","phase":"PHASE4","title":"Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-11-01","conditions":"Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma","enrollment":40},{"nctId":"NCT07269639","phase":"PHASE1, PHASE2","title":"Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2026-01-01","conditions":"Large B-Cell Lymphoma (LBCL)","enrollment":20},{"nctId":"NCT06803693","phase":"PHASE2","title":"Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT03620903","phase":"PHASE2","title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christian Buske","startDate":"2019-09-11","conditions":"Waldenstrom Macroglobulinemia","enrollment":53},{"nctId":"NCT03352765","phase":"PHASE1","title":"A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-20","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT07206823","phase":"NA","title":"Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Primacy Immune Thrombocytopenia","enrollment":30},{"nctId":"NCT07259122","phase":"PHASE2","title":"A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-30","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":43},{"nctId":"NCT02390869","phase":"PHASE3","title":"Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-05","conditions":"Lymphoma, Follicular","enrollment":128},{"nctId":"NCT05099471","phase":"PHASE2","title":"Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia","status":"RECRUITING","sponsor":"Christian Buske","startDate":"2025-03-21","conditions":"Waldenstrom Macroglobulinemia, Treatment Naive","enrollment":80},{"nctId":"NCT04010968","phase":"PHASE2","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-09-27","conditions":"Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy","enrollment":120},{"nctId":"NCT06765317","phase":"PHASE2","title":"A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-01-16","conditions":"Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma","enrollment":42},{"nctId":"NCT01316523","phase":"PHASE2","title":"Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2010-12","conditions":"Non Hodgkin's Lymphoma","enrollment":30},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT07038382","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-08-05","conditions":"Membranous Nephropathy, Lupus Nephritis (LN)","enrollment":24},{"nctId":"NCT06040320","phase":"PHASE1, PHASE2","title":"Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-10-04","conditions":"Post-transplant Lymphoproliferative Disorder","enrollment":12},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT02367040","phase":"PHASE3","title":"Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-03","conditions":"Lymphoma,Non-Hodgkin","enrollment":458},{"nctId":"NCT05270057","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-01-26","conditions":"B-cell Lymphoma, Burkitt Lymphoma","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":825,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rituximab 375","genericName":"Rituximab 375","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}